Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Celerion Appoints Metabolic Diseases Director | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Celerion Appoints Metabolic Diseases Director

Dehn brings substantial expertise in metabolic research tools

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clayton Dehn has been appointed executive director of Metabolic Diseases at Celerion. Mr. Dehn will lead the expansion of the company’s current capabilities that support early proof-of-concept for the development of diabetes, obesity, metabolic and cardio-metabolic interventions.
 
Mr. Dehn has 15 years of experience in drug development and has conducted thousands of glucose clamps (a measure of insulin sensitivity), bringing substantial expertise in a variety of metabolic research tools. He has led successful metabolic programs at two leading CROs, and also served as director of Clinical R&D at a start-up biotech company developing investigational devices, techniques and compounds for use in assisted reproduction.
 
“We are very pleased to have Clayton join the Global Clinical Research team at Celerion,” said Phil Bach, vice president, Global Clinical Research at Celerion. “His comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience will be a great asset to our organization and clients’ drug development programs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics